Marie Frimodt-Møller

​Senior researcher, PhD, team leader
Complications Research

​Contact

E-mail: Marie.frimodt-moeller@regionh.dk
Phone: +45 30 91 30 42

Research area

  1. Diabetic Nephropathy
    - Clinical studies on biomarkes and screeningmethods to identify persons at increased risk for cardiovascular disease and development and progression of diabetic kidney disease.
    - Clinical interventionstudies with medicine aimed at preventing diabetic kidney disease and cardiovascular disease.

  2. Hypertension and arterial stiffness
    - Clinical intervention studies of resistant hypertension
    - Clinical studies with focus on arterial stiffness in relation to intervention and risk stratification.

Current research

 1. PROTON-PeRsOnalising Treatment Of diabetic Nephropathy – consortium grant no. NNF14SA0003
Principal Investigator: Prof. Peter Rossing
Aim: To develop personalised medical treatment for diabetic nephropathy based on a ‘multi-omics’ approach with deep phenotyping of diabetic patients
Collaborators/Partners:
Prof.Dr.Per-Henrik Groop, Helsinki, Finland
Hiddo Lambers Heerspink, University Medical Center Groningen, The Netherlands
Prof.Dr.Andrzej Krolewski, Joslin Diabetes Center, Boston, USA

Including:
2. PROTON – cross sectional study

Principal Investigator: Prof. Peter Rossing
Aim: to look for new mechanisms that underlies the development of kidney disease in type 1 diabetes.
Included is a cross sectional study of glycocalyx , gut-microbiota, authonomic and peripheral neuropathy, FACS analysis, proteomics and metabolomics.
Collaborators:
Ph.D-student Signe Abitz Winther
PROTON-partners as mentioned
Prof.´s Dr.Oluf Borbye Pedersen and Torben Hansen, Center of Metabolism, Copenhagen University
Markku Lehto
Harald Mischak, Mosaiques Diagnostics, Hannover, Germany.

3. PROTON– Authonomic Neuropathy
Principal Investigator: Prof. Peter Rossing
Aim: To examine the relation between authonomic dysfunction and different degrees of diabetic kidney disease as well as its relation to markers of microcirculation, urine proteomics and established cardiovascular biomarkers for endothelial dysfunction.
Collaborators
Ph.D-student: Jens Christian Laursen
PROTON-partners
Prof.Luciano Bernardi and Marco Bordino, Padua University, Italy

4. PROTON - BUTYFUL
Principal Investigator: Prof. Peter Rossing
Aim: To examine the effect of 3 months treatment of sodium-butyrate in patients with type 1 diabetes on intestinal inflammation and albuminuria. Collaborators:
Ph.D-student: Ninna Hahn Tougaard
Ph.D-student Miia Mannerla, Markku Lehto and Prof. Per-Henrik Groop, Folkhälsan Research Center, Finland
PROTON-partners, as mentioned above.

5. PLA2
Principal Investigator: Prof. Peter Rossing
Aim: To determine the prevalence of subclinical cardiovascular disease among asymptomatic individuals with type 2 diabetes and no history of CVD using 3D ultrasound to estimate plaque volume in the common and internal carotid arteries. Secondary, to assess the platelet aggregation, endothelial dysfunction and vascular inflammation and relate these measures to the plaque volume.
Collaborators:
Ph.D-student: Nete Tofte
Prof. Henrik Sillesen, Dept. of Vascular Surgery, Rigshospitalet,
University of Copenhagen.  
Prof. Anne- Mette Hvas
Thrombosis and Haemostasis Research Unit
Aarhus University

6. PLATON
Principal Investigator: Prof. Peter Rossing
Aim: Investigate platelet aggregation in T1D without/off aspirin treatment, stratified according to degree of albuminuria, compared to healthy controls and determine the prevalence of plaques in the carotid arteries in subjects with T1D and the association between platelet aggregation and plaque morphology. Investigate whether platelet aggregation or plaque volume can predict progression in plaque volume after two years and if platelet aggregation and change in plaque volume can predict CVD outcome in register-based follow up, independently of other risk factors.
Collaborators:
Ph.D-student: Christina Gjerslev Poulsen
Prof. Henrik Sillesen, Dept. of Vascular Surgery, Rigshospitalet,
University of Copenhagen.  
Prof. Anne- Mette Hvas
Thrombosis and Haemostasis Research Unit
Aarhus University
  
7. PERL-kidney biopsy
Principal Investigator: Prof. Peter Rossing
Aim: The PERL study is a double-blind randomised clinical study that examines the efficacy of the medicine allopurinol versus placebo on renal function. In the current study, a detailed characterization of participants in the PERL study is pursued, by a kidney biopsy to investigate mechanisms leading to diabetic kidney disease.
Collaborators:
PhD student Christina Gjerlev Poulsen
Consultant Thomas Elung-Jensen and Prof. Bo Feldt-Rasmussen, Dept. of Nephrology.  Rigshospitalet. University of Copenhagen.
Prof.s Markus Bitzer, Frank Brosius and Matthias Kretzler, University of Michigan
Prof. Michael Mauer, University of Minnesota

8. ZIRKUS
Principal Investigator: Med.Sc.D Frederik Persson
Formål: to examine if combination treatment with the potassium binding Lokelma can improve the effect of standard blocking of the renin-angiotensin system, which otherwise can be hampered in the presence of hyperkalemia.
Collaborators:
Ph.D-student Christina Gjerlev Poulsen
Ph.D-student Suvanjaa Sivalingam
Ph.D-student Niels Søndergård Heinrich
Consultant, Ph.D Rikke Borg, Dept. Of Medicine, Sjællands University Hospital Roskilde,
Consultant Hans Furuland, Njursektionen, Specialmedicin, Akademiska Sjukhuset Uppsala.
AstraZeneca AB
GCP-unit, Copenhagen University, Bispebjerg Hospital.

9. RenaKVit-study
Aim: To examine the effect of 12 months of treatment with vitamin K2 on arterial stiffness and bone structure in dialysis patients.
Collaborators:
Ph.D-student Karin Schousboe,
consultant Peter Marckman, dep.of Nephrology, Roskilde University Hospital
consultant Ditte Hansen, Dep. of Nephrology, Herlev University Hospital.

10. The role of Vitamin K in cardiovascular disease and diabetes: epidemiological, clinical and genetic studies
Principal Investigator: Prof. Allan Linneberg.
Aim: To estimate the dietary intake om Vitamin K in a Danish general population and validate biomarkers of functional Vitamin K status against direct measurements of vitamin K metabolites. To investigate if low functional vitamin K status increases CVD risk and incidence of CVD in clinical studies of type 1 and type 2 diabetes with different degrees of kidney impairment as well as in the general population. To investigate the causal effects of vitamin K on the risk of CVD by using genetic variants and the association with vitamin K status and the composition of the gut microbiota.
Collaborators:
Professor Allan Linneberg, Center for clinical research and Prevention.
Betina Heinsbæk Thuesen

 


Responsible editor